Brokerages Expect Genmab A/S (NASDAQ:GMAB) to Post $0.10 Earnings Per Share

Wall Street analysts expect that Genmab A/S (NASDAQ:GMABGet Rating) will announce $0.10 earnings per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Genmab A/S’s earnings. The highest EPS estimate is $0.26 and the lowest is $0.02. Genmab A/S reported earnings per share of $0.27 during the same quarter last year, which would indicate a negative year over year growth rate of 63%. The company is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Genmab A/S will report full-year earnings of $0.78 per share for the current fiscal year, with EPS estimates ranging from $0.63 to $0.87. For the next fiscal year, analysts forecast that the firm will report earnings of $1.13 per share, with EPS estimates ranging from $0.91 to $1.57. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Genmab A/S.

Genmab A/S (NASDAQ:GMABGet Rating) last posted its earnings results on Wednesday, February 16th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.13 by $0.04. Genmab A/S had a return on equity of 14.23% and a net margin of 35.58%. The firm had revenue of $402.74 million for the quarter, compared to analyst estimates of $387.16 million.

GMAB has been the subject of several research reports. Guggenheim downgraded Genmab A/S from a “buy” rating to a “neutral” rating in a research note on Monday, January 3rd. Morgan Stanley cut their price objective on Genmab A/S from $33.00 to $30.00 and set an “underweight” rating for the company in a research report on Tuesday, April 12th. Zacks Investment Research cut Genmab A/S from a “hold” rating to a “sell” rating in a report on Thursday, January 20th. SVB Leerink decreased their price objective on Genmab A/S from $42.00 to $39.00 and set a “market perform” rating on the stock in a research note on Thursday, February 17th. Finally, JPMorgan Chase & Co. cut their target price on shares of Genmab A/S from 3,200.00 to 3,100.00 in a research note on Friday, February 25th. Four analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $480.86.

A number of hedge funds have recently made changes to their positions in GMAB. Liberty Wealth Management LLC boosted its stake in shares of Genmab A/S by 285.6% during the 3rd quarter. Liberty Wealth Management LLC now owns 671 shares of the company’s stock worth $28,000 after buying an additional 497 shares during the last quarter. Cordasco Financial Network grew its stake in Genmab A/S by 40.8% during the third quarter. Cordasco Financial Network now owns 915 shares of the company’s stock worth $40,000 after buying an additional 265 shares in the last quarter. Covestor Ltd bought a new stake in Genmab A/S during the fourth quarter worth $37,000. Bessemer Group Inc. lifted its stake in Genmab A/S by 50.3% in the 4th quarter. Bessemer Group Inc. now owns 1,156 shares of the company’s stock valued at $46,000 after purchasing an additional 387 shares during the last quarter. Finally, Captrust Financial Advisors grew its position in Genmab A/S by 23.2% during the 3rd quarter. Captrust Financial Advisors now owns 1,414 shares of the company’s stock worth $62,000 after acquiring an additional 266 shares during the last quarter. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:GMAB traded up $0.16 during trading on Wednesday, hitting $38.05. 20,372 shares of the stock were exchanged, compared to its average volume of 634,461. The company has a fifty day moving average price of $34.65 and a two-hundred day moving average price of $37.89. The company has a market cap of $25.01 billion, a PE ratio of 52.14, a P/E/G ratio of 1.67 and a beta of 1.04. Genmab A/S has a 12-month low of $30.08 and a 12-month high of $49.07.

Genmab A/S Company Profile (Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Articles

Get a free copy of the Zacks research report on Genmab A/S (GMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.